ArticleTranslational oncology2025
Luteolin suppresses cell migration and invasion via targeting miR-6809-5p/FLOT1/FAK and eliciting EMT in hepatocellular carcinoma.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Elucidating the dual regulation of apoptosis and migration by Ajugasterone C in AGS cells via the PI3K/AKT pathway.Frontiers in pharmacology · 2026Article
- Profiling miRNA in salivary samples from subjects with endometriosis: a pilot study.Frontiers in molecular biosciences · 2026Article
- ITGA5 is overexpressed and promotes tumor progression through SNAI2 in OSCC.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luteolin, 3',4',5,7-tetrahydroxyflavone, a natural flavonoid component found in various Chinese herbs such as Scutellaria barbata D. Don, honeysuckle, chrysanthemum, schizonepeta, and ajuga decumbens, exhibits potential for cancer prevention and therapy. This study elucidates the molecular mechanisms by which luteolin, an active constituent of Scutellaria barbata, inhibits invasion and metastasis of hepatocellular carcinoma (HCC) cell lines both in vitro and in vivo. The oncogenic microRNA miR-6809-5p was found to be aberrantly upregulated in HCC tissues and downregulated by luteolin in HCC cells; overexpression of miR-6809-5p was able to restore the anti-HCC effects of luteolin via the miR-6809-5p/FLOT1/FAK signaling pathway. Furthermore, luteolin suppressed HCC invasion, metastasis, and epithelial-mesenchymal transition (EMT) through modulation of the PI3K/AKT/mTOR pathway, affecting markers such as E-cadherin, β-catenin, Vimentin, N-cadherin, Snail, Twist, and Slug. This research demonstrates that luteolin effectively inhibits HCC cell migration and invasion and significantly suppresses epithelial mesenchymal transition (EMT) both in vitro and in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.